抗抑郁药个体差异的荟萃分析:安慰剂对照随机临床试验
结论不支持仅基于抑郁总分个体化选择抗抑郁药。
要点
- 抗抑郁药与安慰剂的症状反应变异性无显著差异。
- 去甲肾上腺素能药物反应变异性比SSRIs高11%。
- 变异性与基线抑郁严重程度或发表年份无关。
核心结论
- 抗抑郁药与安慰剂的症状反应变异性无显著差异,不支持仅基于抑郁总分进行个体化治疗。
主要发现
- 变异性与基线MDD严重程度或发表年份无关。
临床怎么用
- 临床不应仅依据抑郁总分个体化选择抗抑郁药。
- 去甲肾上腺素能药物反应变异性较高,处方时需考虑个体差异。
局限性
- 不能排除治疗效应异质性可能,未探索个体症状评分或生物标志物与反应变异性的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antidepressants are commonly used to treat major depressive disorder (MDD). Antidepressant outcomes can vary based on individual differences; however, it is unclear whether specific factors determine this variability or whether it is at random. OBJECTIVE: To investigate the assumption of systematic variability in symptomatic response to antidepressants and to assess whether variability is associated with MDD severity, antidepressant class, or study publication year. DATA SOURCES: Data used were updated from a network meta-analysis of treatment with licensed antidepressants in adults with MDD. The Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, and PsycInfo were searched from inception to March 21, 2019. Additional sources were international trial registries and sponsors, drug companies and regulatory agencies' websites, and reference lists of published articles. Data were analyzed between June 8, 2020, and June 13, 2020. STUDY SELECTION: Analysis was restricted to double-blind, randomized placebo-controlled trials with depression scores available at the study's end point. DATA EXTRACTION AND SYNTHESIS: Baseline means, number of participants, end point means and SDs of total depression scores, antidepressant type, and publication year were extracted. MAIN OUTCOMES AND MEASURES: Log SDs (bln σ̂) were derived for treatment groups (ie, antidepressant and placebo). A random-slope mixed-effects model was conducted to estimate the difference in bln σ̂ between treatment groups while controlling for end point mean. Secondary models determined whether differences in variability between groups were associated with baseline MDD severity; antidepressant class (selective serotonin reuptake inhibitors and other related drugs; serotonin and norepinephrine reuptake inhibitors; norepinephrine-dopamine reuptake inhibitors; noradrenergic agents; or other antidepressants); and publication year. RESULTS: In the 91 eligible trials (18 965 participants), variability in response did not differ significantly between antidepressants and placebo (bln σ̂, 1.02; 95% CI, 0.99-1.05; P = .19). This finding is consistent with a range of treatment effect SDs (up to 16.10), depending on the association between the antidepressant and placebo effects. Variability was not associated with baseline MDD severity or publication year. Responses to noradrenergic agents were 11% more variable than responses to selective serotonin reuptake inhibitors (bln σ̂, 1.11; 95% CI, 1.01-1.21; P = .02). CONCLUSIONS AND RELEVANCE: Although this study cannot rule out the possibility of treatment effect heterogeneity, it does not provide empirical support for personalizing antidepressant treatment based solely on total depression scores. Future studies should explore whether individual symptom scores or biomarkers are associated with variability in response to antidepressants.
引用
- Maslej MM, Furukawa TA, Cipriani A, et al. Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. JAMA Psychiatry. 2021. PMID: 33595620. doi:10.1001/jamapsychiatry.2020.4564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。